• Home

  • Documents

  •  · -Dr. Satya Gupta Case-Based: LDL - Hypothesis in back! How to Achieve your Goals? - Dr. Urmil...
4

 · -Dr. Satya Gupta Case-Based: LDL - Hypothesis in back! How to Achieve your Goals? - Dr. Urmil Shah PANEL DISCUSSION QUESTION-ANSWER SGLT2 Inhibitors: Profound CV Renal Benefits

  • Upload
    others

  • View
    0

  • Download
    0

Embed Size (px)

Citation preview

Page 1:  · -Dr. Satya Gupta Case-Based: LDL - Hypothesis in back! How to Achieve your Goals? - Dr. Urmil Shah PANEL DISCUSSION QUESTION-ANSWER SGLT2 Inhibitors: Profound CV Renal Benefits
Page 2:  · -Dr. Satya Gupta Case-Based: LDL - Hypothesis in back! How to Achieve your Goals? - Dr. Urmil Shah PANEL DISCUSSION QUESTION-ANSWER SGLT2 Inhibitors: Profound CV Renal Benefits
Page 3:  · -Dr. Satya Gupta Case-Based: LDL - Hypothesis in back! How to Achieve your Goals? - Dr. Urmil Shah PANEL DISCUSSION QUESTION-ANSWER SGLT2 Inhibitors: Profound CV Renal Benefits
Page 4:  · -Dr. Satya Gupta Case-Based: LDL - Hypothesis in back! How to Achieve your Goals? - Dr. Urmil Shah PANEL DISCUSSION QUESTION-ANSWER SGLT2 Inhibitors: Profound CV Renal Benefits

03.1960 LDL

03.1960 LDL

Documents
Datamatics’ Internal Magazineinsight.datamaticstech.com/esig/Buzz_Oct2014.pdfLaxmikant Nikale (LDL), Yuvraj Vatare (LDL), Seema Adhav (FAS), Shubhangi Patil (LDL), Poonam Naik (LDL)

Datamatics’ Internal Magazineinsight.datamaticstech.com/esig/Buzz_Oct2014.pdfLaxmikant Nikale (LDL), Yuvraj Vatare (LDL), Seema Adhav (FAS), Shubhangi Patil (LDL), Poonam Naik (LDL)

Documents
11.1961 LDL

11.1961 LDL

Documents
Where Do SGLT2 Inhibitors Fit in the Spectrum of Treatment ...eval.peerviewpress.com/content/images/SGLT2.pdfWhere Do SGLT2 Inhibitors Fit in the Spectrum of Treatment of T2DM? Go

Where Do SGLT2 Inhibitors Fit in the Spectrum of Treatment ...eval.peerviewpress.com/content/images/SGLT2.pdfWhere Do SGLT2 Inhibitors Fit in the Spectrum of Treatment of T2DM? Go

Documents
Healthy-Heart-February2020-Volume-11-Issue-123 (Dr. Urmil ... · Dr. Urmil Shah Intracoronary Lithotripsy for the treatment of Calcified Plaque: A Novel Technology Intravascular lithotripsy

Healthy-Heart-February2020-Volume-11-Issue-123 (Dr. Urmil ... · Dr. Urmil Shah Intracoronary Lithotripsy for the treatment of Calcified Plaque: A Novel Technology Intravascular lithotripsy

Documents
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors & Kidney

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors & Kidney

Documents
LDL-C, Non-HDL-C, Measures of LDL Particle …cme.baptisthealth.net/cvdprevention/documents/presentations/2013...LDL-C, Non-HDL-C, Measures of LDL Particle Number (apoB and LDL-P):

LDL-C, Non-HDL-C, Measures of LDL Particle …cme.baptisthealth.net/cvdprevention/documents/presentations/2013...LDL-C, Non-HDL-C, Measures of LDL Particle Number (apoB and LDL-P):

Documents
targets and LDL Non HDL C, - Lipid · PDF fileLDL Cholesterol LDL-C 130 mg/dL LDL-C 130 mg/dL Larger LDL Size Smaller LDL Size LDL cholesterol Non-HDL chol Total / HDL chol LDL size

targets and LDL Non HDL C, - Lipid · PDF fileLDL Cholesterol LDL-C 130 mg/dL LDL-C 130 mg/dL Larger LDL Size Smaller LDL Size LDL cholesterol Non-HDL chol Total / HDL chol LDL size

Documents
08.1961 LDL

08.1961 LDL

Documents
Effects of Dapagliflozin, an SGLT2.ppt

Effects of Dapagliflozin, an SGLT2.ppt

Documents
08.1960 LDL

08.1960 LDL

Documents
11.1960 LDL

11.1960 LDL

Documents
02.1960 LDL

02.1960 LDL

Documents
SGLT2 Inhibitor Agents

SGLT2 Inhibitor Agents

Documents
Metabolism and Atherogenic Properties of LDL · LDL-C Doubly Underestimates CV Risk in case of Small, Dense LDL Large LDL Small, Dense LDL Apo B LDL-C 130 mg/dL FewerParticles & Less

Metabolism and Atherogenic Properties of LDL · LDL-C Doubly Underestimates CV Risk in case of Small, Dense LDL Large LDL Small, Dense LDL Apo B LDL-C 130 mg/dL FewerParticles & Less

Documents
09.1960 LDL

09.1960 LDL

Documents
01.1960 LDL

01.1960 LDL

Documents
Dpp4i vs sglt2 inhibitors against the motion

Dpp4i vs sglt2 inhibitors against the motion

Health & Medicine
10.1960 LDL

10.1960 LDL

Documents
CVOT in Diabetes: Implications for SGLT2 Inhibitors?

CVOT in Diabetes: Implications for SGLT2 Inhibitors?

Documents
SGLT2 Inhibitors: A Dynamic and Evolving Therapeutic Option · SGLT2 inhibitors are not indicated for weight loss Glucose Filtration Glomerulus SGLT2 SGLT1 Distal Tubule Collecting

SGLT2 Inhibitors: A Dynamic and Evolving Therapeutic Option · SGLT2 inhibitors are not indicated for weight loss Glucose Filtration Glomerulus SGLT2 SGLT1 Distal Tubule Collecting

Documents
Scavenger receptors in atherosclerosis...Class B: CD36 + SR-BI Class E: ox LDL SR-PSOX/ CXCL16 Macrophage representation Class G: ox LDL ox LDL ox LDL Class A: Ac LDL ox LDL Class

Scavenger receptors in atherosclerosis...Class B: CD36 + SR-BI Class E: ox LDL SR-PSOX/ CXCL16 Macrophage representation Class G: ox LDL ox LDL ox LDL Class A: Ac LDL ox LDL Class

Documents
Class Update: Sodium-glucose Cotransporter 2 (SGLT2 ... · SGLT2 inhibitors are the newest class of antidiabetic agents for patients with T2DM. SGLT2 inhibitors increase urinary glucose

Class Update: Sodium-glucose Cotransporter 2 (SGLT2 ... · SGLT2 inhibitors are the newest class of antidiabetic agents for patients with T2DM. SGLT2 inhibitors increase urinary glucose

Documents
Healthy Heart (Vol-8, Issue-87) February, 2017 - Dr. Urmil Shah-8 · 2019. 5. 12. · Dr. Urmil Shah From the Desk of Hon. Editor: Dear Friends, Endovascular repair of the aorta,

Healthy Heart (Vol-8, Issue-87) February, 2017 - Dr. Urmil Shah-8 · 2019. 5. 12. · Dr. Urmil Shah From the Desk of Hon. Editor: Dear Friends, Endovascular repair of the aorta,

Documents
SGLT2 Inhibitors and the Clinical Implications of

SGLT2 Inhibitors and the Clinical Implications of

Documents
pejouhesh.sbmu.ac.irpejouhesh.sbmu.ac.ir/article-1-2200-fa.pdfJ, ASLDL LDL , IGT LDL J, *ASLDL LDL A/o >.r. LDL / HDL .(r

pejouhesh.sbmu.ac.irpejouhesh.sbmu.ac.ir/article-1-2200-fa.pdfJ, ASLDL LDL , IGT LDL J, *ASLDL LDL A/o >.r. LDL / HDL .(r

Documents
SGLT2 inhibition in diabetes: extending from glycaemic

SGLT2 inhibition in diabetes: extending from glycaemic

Documents
Cardiovascular Protection by SGLT2 Inhibitors Possible ......Urinary glucose excretion via SGLT2 inhibition Bakris et al. Kidney Int 2009;75:1272–7. SGLT2 SGLT2 inhibitor SGLT1 SGLT2

Cardiovascular Protection by SGLT2 Inhibitors Possible ......Urinary glucose excretion via SGLT2 inhibition Bakris et al. Kidney Int 2009;75:1272–7. SGLT2 SGLT2 inhibitor SGLT1 SGLT2

Documents
Acp Sglt2 Slidecast 220

Acp Sglt2 Slidecast 220

Documents
09.1961 LDL

09.1961 LDL

Documents